Could Pfizer nab AstraZeneca with pipeline-based payouts? Maybe, but cash is easier

When Sanofi ($SNY) bought Genzyme, the deal was clinched on a contingent value right (CVR) based on the potential multiple sclerosis treatment Lemtrada. Could Pfizer ($PFE) do the same thing to win over AstraZeneca ($AZN)? Some analysts think so. But others think it's too complicated, given AstraZeneca's range of pipeline treatments and long-term timeframe. The simpler alternative: More cash. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.